Design and evaluation of antigen-specific vaccination strategies against cancer.

[1]  T. Schumacher,et al.  In situ detection of virus- and tumor-specific T-cell immunity , 2000, Nature Medicine.

[2]  T. Chao,et al.  An autologous oral DNA vaccine protects against murine melanoma. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[3]  A. Mackensen,et al.  Phase I study in melanoma patients of a vaccine with peptide‐pulsed dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells , 2000, International journal of cancer.

[4]  D. Jäger,et al.  Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[5]  D. McNeel,et al.  Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  T. Whiteside,et al.  Evaluation of the Modified ELISPOT Assay for Gamma Interferon Production in Cancer Patients Receiving Antitumor Vaccines , 2000, Clinical Diagnostic Laboratory Immunology.

[7]  D. Schadendorf,et al.  Phase 2 Trial of Vaccination With Tyrosinase Peptides and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma , 2000, Journal of immunotherapy.

[8]  H. Grey,et al.  Detection of T Helper Responses, But Not of Human Papillomavirus-Specific Cytotoxic T Lymphocyte Responses, After Peptide Vaccination of Patients With Cervical Carcinoma , 2000, Journal of immunotherapy.

[9]  A. Gross,et al.  Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybrids , 2000, Nature Medicine.

[10]  E. Appella,et al.  A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  Mark M. Davis,et al.  The Use of HLA A2.1/p53 Peptide Tetramers to Visualize the Impact of Self Tolerance on the TCR Repertoire1 , 2000, The Journal of Immunology.

[12]  A. Fiander,et al.  Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens. , 2000, Cancer research.

[13]  M. Probst-Kepper,et al.  Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. , 2000, Immunity.

[14]  J. Schlom,et al.  Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  S. H. van der Burg,et al.  Strategies for immunotherapy of cancer. , 2000, Advances in immunology.

[16]  Jonathan J. Lewis,et al.  Coupling and Uncoupling of Tumor Immunity and Autoimmunity , 1999, The Journal of experimental medicine.

[17]  A. Enk,et al.  Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma , 1999, The Journal of experimental medicine.

[18]  S. Steinberg,et al.  Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. , 1999, Journal of immunology.

[19]  A. Sckell,et al.  Targeting HER‐2/neu for active‐specific immunotherapy in a mouse model of spontaneous breast cancer , 1999, International journal of cancer.

[20]  F. Sallusto,et al.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.

[21]  Craig W. Reynolds,et al.  Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma , 1999, Nature Medicine.

[22]  S. Groshen,et al.  Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  D. Speiser,et al.  High Frequencies of Naive Melan-a/Mart-1–Specific Cd8+ T Cells in a Large Proportion of Human Histocompatibility Leukocyte Antigen (Hla)-A2 Individuals , 1999, The Journal of experimental medicine.

[24]  V. Cerundolo,et al.  An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (Ctl)-Defined, Melanocyte-Specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-Specific Ctls but Does Not Overcome Tumor Escape from Immune Surveillance in Metastatic Lesions , 1999, The Journal of experimental medicine.

[25]  E. Celis,et al.  A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. , 1999, Journal of immunotherapy.

[26]  D. Schadendorf,et al.  Cell-based vaccination against melanoma – background, preliminary results, and perspective , 1999, Journal of Molecular Medicine.

[27]  D. Speiser,et al.  Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376. , 1999, Cancer research.

[28]  S. Steinberg,et al.  Immune selection after antigen-specific immunotherapy of melanoma. , 1999, Surgery.

[29]  L. Sherman,et al.  Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens. , 1999, Journal of immunology.

[30]  G. Ogg,et al.  Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma. , 1999, Journal of immunology.

[31]  Reen,et al.  Rapid conversion of naive to effector T cell function counteracts diminished primary human newborn T cell responses , 1999, Clinical and experimental immunology.

[32]  G. Hämmerling,et al.  Autoaggression and tumor rejection: it takes more than self‐specific T‐cell activation , 1999, Immunological reviews.

[33]  Mario Roederer,et al.  Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients , 1999, Nature Medicine.

[34]  M. Cheever,et al.  Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  E. Engleman,et al.  Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study. , 1999, Blood.

[36]  F. Holding,et al.  Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. , 1999, The Journal of infectious diseases.

[37]  L. Esserman,et al.  Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice , 1999, Cancer Immunology, Immunotherapy.

[38]  F. Guadagni,et al.  Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. , 1999, Cancer research.

[39]  P. Coulie,et al.  Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 , 1999, International journal of cancer.

[40]  A. Amici,et al.  Genetic immunization against neu /erbB2 transgenic breast cancer , 1998, Cancer Immunology, Immunotherapy.

[41]  G. Ogg,et al.  Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes , 1998, The Journal of experimental medicine.

[42]  F. Marincola,et al.  Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  P. Marrack,et al.  Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. , 1998, Immunity.

[44]  C. Kurts,et al.  Cross-tolerance: A Pathway for Inducing Tolerance to Peripheral Tissue Antigens , 1998, The Journal of experimental medicine.

[45]  J. Witte,et al.  Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[47]  C. Melief,et al.  Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors , 1998, The Journal of experimental medicine.

[48]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[49]  R. Offringa,et al.  Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[50]  J. Schlom,et al.  Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. , 1997, Cancer research.

[51]  S. H. van der Burg,et al.  HIV-1 reverse transcriptase-specific CTL against conserved epitopes do not protect against progression to AIDS. , 1997, Journal of immunology.

[52]  G. Fleuren,et al.  Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes , 1997, The Journal of experimental medicine.

[53]  A. Houghton,et al.  Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[54]  L. Fugger,et al.  Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[55]  C. Ho,et al.  Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes. , 1996, Journal of immunology.

[56]  E. Sercarz,et al.  Harnessing self-reactivity in cancer immunotherapy. , 1996, Seminars in immunology.

[57]  R. Offringa,et al.  Peptide-based cancer vaccines. , 1996, Current opinion in immunology.

[58]  S. Stacey,et al.  A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer , 1996, The Lancet.

[59]  J. Karbach,et al.  Generation of cytotoxic T‐cell responses with synthetic melanoma‐associated peptides in vivo: Implications for tumor vaccines with melanoma‐associated antigens , 1996, International journal of cancer.

[60]  A. Hart,et al.  Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2. , 1995, Cancer research.

[61]  M. Mathieu,et al.  Primary proliferative T cell response to wild‐type p53 protein in patients with breast cancer , 1995, European journal of immunology.